The other one relapsed locally after 8 years and is again in complete remission. In medicine, you can't explain why some patients are doing well, while other patients are relapsing. After the French study on autologous stem cell transplantation, optimistic outcomes were projected. Today, it can be accepted that aside from a gain in survival, the gain in quality of life is clear. The time between therapy and relapse is event free and without treatment.
Quality of life is extremely good.
The real indication of autologous stem cell transplantation will be if an extended survival benefit is reached. That is why these controlled therapy protocols are important. But all the schemes are nearly the same. We are not doing second transplants at the moment. We would like to wait until the results come out.